Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

Tuesday, November 29, 2022

ANI Pharmaceuticals, Inc., announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL.

ANI’s Fluoxetine Oral Solution is the generic version of the Reference Listed Drug (RLD) Prozac®. The current annual U.S. market for Fluoxetine Oral Solution is approximately $14.6 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.

"We continue to strengthen our generics business with new product launches, and laud the efforts of our R&D team in helping the Company fulfill its ongoing commitment to provide affordable generic alternatives to customers and patients in need,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024